Ipamorelin vs SHLP2
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Side-by-Side Comparison
| Aspect | Ipamorelin | SHLP2 |
|---|---|---|
| Mechanism | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. |
| Typical Dosage | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. |
| Administration | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. |
| Side Effects | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. |
| Best For |
What They Have in Common
Both Ipamorelin and SHLP2 are commonly used for: